AdaptHealth’s second quarter results prompted a significant negative market reaction, as the company reported both revenue and profitability well below Wall Street’s expectations. Management attributed this to a combination of operational inefficiencies in its large West Coast capitated contract and cost pressures from a sudden supplier price increase. CEO Suzanne Foster described the unexpected operational challenges as “not sustainable,” highlighting elevated costs from higher-than-anticipated order volumes and inefficient workflows. Foster also acknowledged that restructuring efforts, including workforce reductions and portfolio simplification, were necessary to address these immediate pressures.

Is now the time to buy AHCO? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From AdaptHealth’s Q2 Earnings Call

• Michael Murray (RBC Capital Markets) questioned the magnitude and segmentation of the $30 million supplier price impact. CEO Suzanne Foster declined to specify the affected segment but outlined efforts to offset the cost, adding that “mid-year, we do not…have the opportunity to pass through price.”
• Brian Tanquilut (Jefferies) asked whether AdaptHealth’s divestitures signal a strategic shift toward a smaller business. Foster explained the company’s intent to “shrink down to our core and build from there,” emphasizing the focus on Sleep and Respiratory.
• Pito Chickering (Deutsche Bank) pressed on the sustainability and margin profile of capitated contracts compared to fee-for-service. Foster reiterated the long-term strategic value of capitation but acknowledged current operational headwinds prevent near-term margin realization.
• Richard Close (Canaccord Genuity) asked if the company’s 20% margin target for capitated contracts depends on achieving the “halo effect” from additional business. Foster clarified that the margin target excludes such upside, which is considered incremental.
• Kevin Caliendo (UBS) challenged the abrupt manufacturer contract termination and price increase. Foster described the event as “unusual” and surprising, noting the company was not given advance warning and is working to resolve it.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will closely watch (1) the pace of operational improvements and cost normalization in the West Coast capitated contract, (2) the outcome of ongoing supplier price negotiations and their effect on gross margins, and (3) execution against the company’s technology-driven efficiency strategy. The resolution of these issues will be critical for AdaptHealth’s ability to deliver on its streamlined business model.

AdaptHealth currently trades at $5.27, down from $10.83 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.